707541-47-7

Usage

Uses

Used in Pharmaceutical Industry:
5-Fluoro-3H-spiro[isobenzofuran-1,4'-piperidin]-3-one is used as a therapeutic agent for the treatment of neurological and psychiatric disorders. Its agonistic effect on the serotonin 5-HT1A receptor makes it a potential candidate for managing conditions such as anxiety, depression, and schizophrenia, where modulation of this receptor is believed to have beneficial effects on mood and cognition.
Used in Neuroscience Research:
In the field of neuroscience, 5-Fluoro-3H-spiro[isobenzofuran-1,4'-piperidin]-3-one serves as a valuable research tool. It is utilized to investigate the role of 5-HT1A receptors in the brain's response to various stimuli and conditions. Understanding these mechanisms can provide insights into the development of new treatments for neurological and psychiatric disorders, as well as enhance our knowledge of the brain's complex signaling pathways.

Upstream product

• 644968-61-6 1'-benzyl-5-fluoro-3H-spiro[2-benzofuran-1,4'-piperidine]-3-one 

Relevant academic research and scientific papers

SPIRO-5,6-DIHYDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENES

The present invention is concerned with spiro-dihydrotetraazabenzoazulenes, i.e. spiro-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulenes of formula I wherein R1, R2, R3, X, Y, Z, m and n are as described herein. The compounds according to the invention act as V1a receptor modulators and are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

INDOL-3-YL-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS

The invention relates to indol-3-yl-carbonyl-spiro-piperidine derivatives which act as V1a receptor antagonists and which are represented by Formula I: wherein the spiro-piperidine head group A and the residues R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions containing such compounds, methods for preparing the compounds and pharmaceutical compositions, and their use in the treatment of dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxious and depressive disorders.